^
Association details:
| Biomarker: | NF1 D1644A |
|---|---|
| Cancer: | Head and Neck Cancer |
| Drug: | everolimus (mTOR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus
Excerpt:
The assay reported TP53 (Q38fs) mutation and NF1 (D1644A) mutation...a therapeutic attempt using everolimus 10mg once per day was initiated...His tumor showed further decrease in SUVmax in the PET-CT scan taken after 4 months of therapy (Supplementary Figure 3). The partial response was maintained for 8 months.
DOI:
10.18632/oncotarget.7234
